Equities Analysts Set Expectations for ENTA FY2026 Earnings

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) – Equities research analysts at HC Wainwright lowered their FY2026 earnings estimates for shares of Enanta Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 11th. HC Wainwright analyst B. Folkes now anticipates that the biotechnology company will post earnings of ($2.49) per share for the year, down from their prior forecast of ($2.18). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Enanta Pharmaceuticals’ current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q4 2026 earnings at ($0.95) EPS, FY2027 earnings at ($2.66) EPS, FY2028 earnings at ($3.37) EPS, FY2029 earnings at ($2.55) EPS and FY2030 earnings at ($2.17) EPS.

ENTA has been the topic of several other reports. Wall Street Zen cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $19.50.

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $13.50 on Thursday. Enanta Pharmaceuticals has a 1-year low of $6.60 and a 1-year high of $17.15. The business has a fifty day moving average price of $13.18 and a 200-day moving average price of $13.44. The stock has a market capitalization of $392.58 million, a P/E ratio of -5.60 and a beta of 0.98.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The business had revenue of $14.36 million for the quarter, compared to analysts’ expectations of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.61%.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Large investors have recently made changes to their positions in the company. Deutsche Bank AG boosted its position in shares of Enanta Pharmaceuticals by 4.6% during the fourth quarter. Deutsche Bank AG now owns 24,107 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 1,055 shares during the last quarter. Public Employees Retirement System of Ohio increased its holdings in Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 14,412 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 1,100 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in Enanta Pharmaceuticals by 8.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 18,007 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 1,383 shares during the last quarter. Quantinno Capital Management LP lifted its stake in Enanta Pharmaceuticals by 4.9% in the 1st quarter. Quantinno Capital Management LP now owns 35,122 shares of the biotechnology company’s stock worth $444,000 after purchasing an additional 1,627 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in Enanta Pharmaceuticals by 13.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 16,443 shares of the biotechnology company’s stock worth $197,000 after purchasing an additional 1,940 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.